Sun Pharmaceutical

Cellix Bio Pharma Completes the Acquisition of Avaca Pharma

Tuesday, August 4, 2020 - 11:30pm

Cellix Bio Pharma completes the acquisition of Avaca Pharma, a formulation development company.

Key Points: 
  • Cellix Bio Pharma completes the acquisition of Avaca Pharma, a formulation development company.
  • The acquisition of Avaca Pharma provides Cellix Bio Pharma with world-class expertise in NME/NCE discovery R&D services and a unique and extensive set of high-content and complex formulations.
  • Cellix Bio Pharma is a wholly-owned subsidiary of Cellix Bio.
  • More information on Cellix Bio Pharma: www.cellixbiopharma.com
    Avaca Pharma is a new-gen pharmaceutical development and commercialization organization with a vision to innovate for better health.

Jay Pharma to File IND Applications to FDA for a clinical study of proprietary formulations in Radiodermatitis and a combination Therapy in Glioblastoma

Wednesday, July 29, 2020 - 2:00pm

"Jay Pharma is seeking to bring oncology drugs to the market through FDA approval," said Dave Johnson, Jay Pharma's CEO-elect.

Key Points: 
  • "Jay Pharma is seeking to bring oncology drugs to the market through FDA approval," said Dave Johnson, Jay Pharma's CEO-elect.
  • "Jay Pharma is poised to enter an exciting new stage of growth, and I am delighted to be a part of it," Wilkins said.
  • "We will work closely to ensure Jay Pharma is properly structured to work with the FDA and other regulatory agencies around the world."
  • According to Johnson, the Company plans to enter clinical trials for both its radiodermatitis and GBM formulations upon receipt of FDA clearance.

Competitive Intelligence Solution Helps A Pharmaceutical Company Reduce Operational Cost By 30% | Infiniti’s Recent Engagement for A Pharma Secondary Packaging Market Client

Tuesday, June 30, 2020 - 12:16pm

(Graphic: Business Wire)

Key Points: 
  • (Graphic: Business Wire)
    In pharmaceuticals, secondary packaging constitutes the packaging which does not come in direct contact with the dosage form.
  • Business challenge: A prominent pharmaceutical company headquartered in San Francisco, CA sought to explore the changing trends in the secondary pharma packaging market by focusing the research on major design/technology innovations and best practices adopted by leading players in the pharma secondary packaging market.
  • By leveraging Infinitis competitive intelligence solution, the pharmaceutical company wanted to understand the competitor landscape in the US and European pharma secondary packaging market, new features of secondary packaging being incorporated by competitors, product portfolio descriptions, and competitor strategies to promote adherence.
  • Want comprehensive insights into the market drivers, challenges, key industry players, and more in the pharma secondary packaging market?

Pharmaceutical Executive® Reveals 20th Annual Pharma 50 for 2020

Friday, June 12, 2020 - 3:06pm

Pharmaceutical Executive, a multimedia platform for industry leaders to exchange experiences and insights about innovative business and marketing ideas, has released its annual Pharma 50 list for 2020.

Key Points: 
  • Pharmaceutical Executive, a multimedia platform for industry leaders to exchange experiences and insights about innovative business and marketing ideas, has released its annual Pharma 50 list for 2020.
  • Now in its 20th year, the comprehensive list reveals how brand surges, new ranking battles and mergers and acquisitions have reshaped company positioning.
  • For 20 years, Pharmaceutical Executives Pharma 50 annual list has provided an insightful look into the sales performances of the top 50 biopharma companies in the industry, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, the parent company of Pharmaceutical Executive.
  • Data for the Pharma 50 listings are provided in partnership with life sciences market intelligence firm Evaluate Ltd via its EvaluatePharma service.

Sun Pharma Plans to Present Clinical Insights from 25 Data Abstracts Across its Dermatology Portfolio at the 2020 AAD Virtual Meeting Experience

Thursday, June 11, 2020 - 1:00pm

PRINCETON, N.J., June 11, 2020 /PRNewswire/ --Sun Pharmaceutical Industries Inc., USA (SPII) "Sun Pharma" today announced 25 data abstracts from its dermatology portfolio will be presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020.

Key Points: 
  • PRINCETON, N.J., June 11, 2020 /PRNewswire/ --Sun Pharmaceutical Industries Inc., USA (SPII) "Sun Pharma" today announced 25 data abstracts from its dermatology portfolio will be presented at the American Academy of Dermatology (AAD) Virtual Meeting Experience 2020.
  • The data presentations will highlight key clinical insights on ILUMYA (tildrakizumab-asmn), ODOMZO (sonidegib) and LEVULAN KERASTICK (aminolevulinic acid HCl) + BLU-U.
  • Click to Tweet #NEWS: @SunPharma_Live announces 25 abstracts revealing clinical insights from its dermatology portfolio to be to be included in #AADVMX2020.
  • ILUMYA(tildrakizumab-asmn) Abstracts for Moderate-to-Severe Plaque Psoriasis and Psoriatic Arthritis:
    Early and Maintained Response Levels in Psoriasis Patients Treated with Tildrakizumab (Abstract #17113).

Fosun Pharma Invites Chinese and Foreign Experts to Jointly Discuss Prevention and Control Measures of COVID-19 Epidemic in Africa

Wednesday, April 29, 2020 - 5:50pm

Since the COVID-19 outbreak, Fosun Pharma, an international pharmaceutical company, has taken an active part in the battle.

Key Points: 
  • Since the COVID-19 outbreak, Fosun Pharma, an international pharmaceutical company, has taken an active part in the battle.
  • Mr. Wu Yifang, President and CEO of Fosun Pharma, said, "Fosun Pharma has been operating in Africa for over decade and has nearly 1,000 employees there.
  • We are striving to control the spread of the epidemic by strengthening various case management measures."
  • Fosun Pharma hopes that these materials will help alleviate the burden on local health systems, facilitating the countries to reach their malaria prevention and control targets.

Fosun Pharma Receives FDA Emergency Use Authorization (EUA) For Its COVID-19 RT-PCR Detection Kit

Sunday, April 19, 2020 - 1:00pm

SHANGHAI, April 19, 2020 According to the website of the U.S. Food and Drug Administration ("FDA"), Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK) has received emergency use authorization (EUA) from FDA for itsCOVID-19 RT-PCR detection kit.

Key Points: 
  • SHANGHAI, April 19, 2020 According to the website of the U.S. Food and Drug Administration ("FDA"), Shanghai Fosun Pharmaceutical (Group) Co., Ltd ("Fosun Pharma"; Stock Code: 600196.SH, 02196.HK) has received emergency use authorization (EUA) from FDA for itsCOVID-19 RT-PCR detection kit.
  • The testing kit which was self-developed by Fosun Long March, a wholly-owned subsidiary of Fosun Pharma, has received the medical device registration certificate issued by the China National Medical Products Administration (NMPA) and granted CE certification from the European Union ("EU").
  • Fosun Pharma has been engaged in the business of PCR hepatitis B virus diagnostic reagents since its establishment in 1994.
  • According to the company's FY2019 earnings results, the revenue of Fosun Pharma increased by 14.72% to RMB28,585million as compared to 2018.

Sun Pharmaceutical Industries, Inc. Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment

Friday, March 27, 2020 - 7:00pm

Sun Pharma is seeking to enable health care experts meet the growing patient demands for this product as they assess its potential to treat COVID-19 through clinical trials.

Key Points: 
  • Sun Pharma is seeking to enable health care experts meet the growing patient demands for this product as they assess its potential to treat COVID-19 through clinical trials.
  • Hydroxychloroquine sulfate tablets manufactured by Sun Pharma are approved by the U.S. Food and Drug Administration (FDA) for the treatment of a range of conditions including malaria, lupus erythematosus and rheumatoid arthritis.
  • Hydroxychloroquine is not currently approved for use in the treatment of COVID-19; however, it is currently under investigation as a possible treatment option for coronavirus.
  • About Sun Pharmaceutical Industries Ltd. (CIN - L24230GJ1993PLC019050):
    Sun Pharmaceutical Industries Inc., USA is a wholly owned subsidiary of Sun Pharma, world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Sun Pharma Launches New Ad Campaign to Raise Awareness of Acne and its Impact on Everyday Life

Monday, February 10, 2020 - 12:45pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200210005147/en/
    The Take on Acne ads depict the disruptive nature of powerful and painful acne breakouts that often seem to come out of nowhere.
  • The ad concept is the result of research Sun Pharma conducted to understand how acne impacts teens and young adults, and how they experience this condition in their own words.
  • Its also important that people know that some forms of acne are medical conditions that require clinical intervention.
  • About Sun Pharmaceutical Industries Ltd.
    Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.

Rockwell Medical, Inc. Enters into Exclusive License and Supply Agreements with Sun Pharma for the Rights to Commercialize Triferic® in India

Wednesday, January 15, 2020 - 2:30am

Under the terms of the agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic in India and Rockwell Medical will supply the product to Sun Pharma.

Key Points: 
  • Under the terms of the agreements, Sun Pharma will be the exclusive development and commercialization partner for Triferic in India and Rockwell Medical will supply the product to Sun Pharma.
  • Sun Pharma will leverage its market leading nephrology franchise to promote Triferic to nephrologists in India.
  • A Joint Alliance Committee, comprised of members from Rockwell Medical and Sun Pharma, will guide the development and execution for Triferic in India.
  • We are pleased to establish this important relationship with Sun Pharma, which has a strong presence in the nephrology segment in India.